SINTESIS SENYAWA 3-BENZILIDENAMINO-2-(3,4-DIKLOROFENIL) KUINAZOLIN-4(3H)-ON TERSUBSTITUSI DAN UJI AKTIVITAS ANTIPLATELET PADA Mus musculus DENGAN METODE SLIDE CLOTTING TIME

• Main Author: GALIH SATRIO PUTRA, 051514153029
• Format: Theses and Dissertations NonPeerReviewed
• Language: English; English
• Published: 2017
• Subjects: RS Pharmacy and materia medica
• Online Access: http://repository.unair.ac.id/66434/1/abstrak.pdf; http://repository.unair.ac.id/66434/2/tesis-sintesis-galih.compressed.pdf; http://repository.unair.ac.id/66434/
• Institution: Universitas Airlangga

The specific objective of this research is to synthesize 3-substituted (benzylideneamino)-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one compounds from anthranilic acid and study their biological activity as antiplatelet through ex vivo study on Mus musculus by slide clotting time method. To obtained 3-substituted-(benzylideneamino)-2-(3,4-dichlorophenyl)- quinazolin-4(3H)-one compounds through 3 stages of reaction. On the stage I, anthranilic acid was reacted with 3,4-dichlorobenzoyl chloride and obtained 2- (3,4-dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one. On the stage II, 2-(3,4- dichlorophenyl)-4H-benzo[d][1,3]oxazin-4-one was reacted with hydrazine and obtained 3-amino-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one. On the Stage III, 3-amino-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one was reacted with benzaldyhide and its derivatives such as 4-methoxy benzaldyhide, 4- dimethylamino benzaldyhide and 4-nitro benzaldyhide and finally obtained four coumpunds of 3-(benzylideneamino)-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one derivatives. All structures of the compounds were confirmed by UV-Vis Spectrophotometry, 1H-NMR, 13C-NMR, FT-IR and MS Spectroscopic methods. The yield of 3-(benzylideneamino)-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one derivatives around 59-67 %. The result of antiplatelet ex vivo study by slide clotting time method., Some of 3-(benzylideneamino)-2-(3,4-dichlorophenyl)quinazolin-4(3H)-one derivatives has better antiplatelet activity than acetylsalicylic acid (ASA). 3-((4-nitrobenzylidene)amino)-2-phenylquinazolin-4(3H)-one has the lowest ED50 (0.016 mmol/ Kg body weight of mice) and therefore potential to be further as a candidate antiplatelet agent